The Biosimilars Drugs Clinical Pipeline 2021​


​Release Date: Q2' 2021
Number of Candidates: 72

Synopsis: Biosimilars are biochemicals with composition similar to reference biologics, generating a pathway for affordable access to treatments for chronic diseases. The biosimilar market is continuing to mature, steadily expanding in highly regulated as well as non-regulated regions. As compared to the generic drugs market, biosimilars are facing greater challenges, specifically high R&D costs and lengthy patent litigation. Since the shift to accepting biosimilars has been a gradual one, there are significant untapped opportunities for players in the biosimilar ecosystem to take a chunk of the sizable biologics market.

​Uptake of biosimilars is starting to gain momentum in 2021 and expected to grow significantly by the end of the decade. As stakeholders understand and recognize the benefits offered by biosimilars, legislation and regulatory changes will soon follow to bring the biosimilar market to full fruition. In the coming years, we expect biosimilars to experience more tolerant regulation, quicker approvals, and increased interchangeability.
The “Biosimilars Drugs Pipeline 2021” excel sheet presents a look at the major drug candidates currently in the clinical pipeline. The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the biosimilars drugs market, profiling 72 future candidates.
For a Sample and Inquiries please contact [email protected]

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate (Name)
  • Drug Developer(s)
  • Phase
    • Phase I
    • Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Clinical
    • Pre-Registration
  • Active Substance ​
    • Adalimumab
    • Aflibercept
    • Bevacizumab
    • Corifollitropin Alfa
    • Darbepoetin Alfa
    • Denosumab
    • Eculizumab
    • Enoxaparin Sodium
    • Epoetin alfa
    • Etanercept
    • Factor VIIa-CTP
    • Insulin glargine
    • Natalizumab
    • Omalizumab
    • Pegfilgrastim
    • Ranibizumab 
    • Rituxan
    • Rituximab
    • Somatrogon
    • Somatropin
    • Tocilizumab 
    • Trastuzumab
    • Ustekinumab
  • Therapeutic Area
  • Mechanism of Action